Physician profile
Charisma Lee
NPI 1851865406
$2,410.09
in general payments reported to CMS, 2019-2025
19 companies · $647 in 2025
The $647 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.75 · 2023: $1,178 · 2024: $558 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $438.14 | 2023 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $379.11 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $284.05 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Alexion Pharmaceuticals, INC. | $254.79 | 2023-2025 | Ultomiris |
| Sobi, INC | $193.48 | 2023-2025 | |
| Daiichi Sankyo INC. | $173.85 | 2023-2025 | Injectafer, Enhertu |
| Genzyme Corporation | $99.36 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $97.44 | 2025 | Monoferric |
| Immunocore Limited | $74.61 | 2023-2024 | Kimmtrak |
| Shield Therapeutics INC | $73.98 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $68.93 | 2025 | Empaveli |
| Regeneron Healthcare Solutions, INC. | $66.64 | 2023 | Libtayo |
| Janssen Biotech, INC. | $50.94 | 2022-2023 | Rybrevant |
| Emd Serono, INC. | $30.59 | 2024 | |
| Merck Sharp & Dohme LLC | $28.41 | 2025 | Keytruda |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $27.49 | 2023 | Tivdak |
| Stemline Therapeutics INC. | $25.84 | 2024 | Orserdu |
| Chiesi USA, INC. | $21.56 | 2024 | Ferriprox |
| Astellas Pharma US INC | $20.88 | 2025 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charisma Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.